Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.67 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9010035 | 0.94 | PARP1 (0.59) | PARP1PARP2KDM4ECYP1A2CYP3A4 | |
| SCHEMBL6795915 | 0.93 | PARP1 (0.70) | PARP1PARP2TNKSTNKS2HTR1A | |
| SCHEMBL14129617 | 0.91 | PARP1 (0.64) | PARP1PARP2TNKSTNKS2HTR1A | |
| SCHEMBL16432166 | 0.87 | PARP1 (0.69) | PARP1PARP2TNKSTNKS2 | |
| SCHEMBL18729762 | 0.83 | PARP1 (0.61) | PARP1PARP2TNKSTNKS2 | |
| SCHEMBL18730877 | 0.83 | PARP1 (0.59) | PARP1PARP2TNKSTNKS2 | |
| SCHEMBL14264637 | 0.82 | HTR2A (0.54) | PARP1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9010001 | 0.81 | PARP1 (0.57) | PARP1PARP2HTR2A | |
| SCHEMBL16432069 | 0.80 | PARP1 (0.70) | PARP1PARP2TNKSTNKS2 | |
| SCHEMBL9009912 | 0.79 | PARP1 (0.67) | PARP1PARP2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158673-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-08 | — | — | US | disclosed |
| US-9522905-B2 | Quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-20 | — | — | US | disclosed |
| US-20140080835-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-20 | — | — | US | disclosed |
| US-8188103-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-8188103-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | VAN DER AA MARCEL JOZEF MARIA | 2011-03-31 | — | — | US | disclosed |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | VAN DER AA MARCEL JOZEF MARIA | 2011-03-31 | — | — | US | disclosed |
| US-7875621-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| US-7875621-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | JANSSEN PHARMACEUTICA, NV (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | JANSSEN PHARMACEUTICA, NV (BE) | 2008-07-24 | — | — | US | disclosed |
| US-4522945-A | SEROTONINE ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-11 | — | — | US | disclosed |
| EP-0013612-B1 | (PIPERIDINYLALKYL)QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-11-09 | — | — | EP | disclosed |
| US-4335127-A | POTENT SEROTONIN ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-06-15 | — | — | US | disclosed |
| EP-0013612-A2 | (Piperidinylalkyl)quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885KDM4E 3137/4885 |
| US-20140080835-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP3, PARP2 | PARP1 1/4885PARP2 3/4885KDM4E 835/4885 |
| US-20170158673-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP3, PARP2 | PARP1 1/4885PARP2 3/4885KDM4E 835/4885 |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885KDM4E 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.